Comparison of Triggering Final Oocyte Maturation with Follicle Stimulating Hormone Plus Human Chorionic Gonadotropin, versus Human Chorionic Gonadotropin Alonein Normoresponder Women Undergoing Intracytoplasmic Sperm Injection: A Randomized Clinical Trial

Document Type : Original Article


1 Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran

2 Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran


Background: Few studies have so far been done about the role of follicle stimulating hormone (FSH) in final oocyte
maturation. However, none of these studies have been performed solely on normoresponder patients. This study aimed
to determine whether oocyte maturation, as well as fertilization and pregnancy rates, could be improved in normoresponder women with concomitant FSH and human chorionic gonadotropin (hCG) trigger compared to those with the hCG trigger alone.
Materials and Methods: In this prospective randomized clinical trial, 117 normoresponder women, aged 19-40 years
who were candidates for the gonadotropin-releasing hormone (GnRH) antagonist protocol at Avicenna Infertility
treatment Center, were enrolled and claasified in two groups. Final oocyte maturation was triggered using 10000 IU of
hCG plus 450 IU of FSH in the first group (59 subjects) and 10000 IU of hCG alone in the second group (58 subjects).
The primary outcome was clinical pregnancy rate.
Results: Mean age of the patients was 33.21 ± 4.41 years. There was no difference in clinical pregnancy among the
two groups (30.9% vs. 25.5%, P=0.525). There was no statistically significant difference in fertilization rate (80.0%
vs. 74.1%, P=0.106), implantation rates (18.9% vs. 16.7%, P=0.352), and chemical pregnancy rates (38.2% vs. 32.7%,
P=0.550). Oocyte maturation rate (84.2% vs. 73.6%, P<0.001), 2 pronuclei (2PNs) (6.53 ± 2.54 vs. 5.36 ± 2.85,
P=0.021) and total embryos (5.85 ± 2.43 vs. 4.91 ± 2.58, P=0.046) were significantly higher in the first group.
Conclusion: Adding FSH to hCG for oocyte triggering, significantly improved oocyte maturation rates and total embryos.
While there was no significant difference in the clinical and chemical pregnancy rates, between these two groups
(registration number: IRCT20190108042285N1).


  1. Qiu Q, Huang J, Li Y, Chen X, Lin H, Li L, et al. Does an FSH surge at the time of hCG trigger improve IVF/ICSI outcomes? A randomized, double-blinded, placebo-controlled study. Hum Reprod. 2020; 35(6): 1411-1420.
  2. Chen CH, Tzeng CR, Wang PH, Liu WM, Chang HY, Chen HH, et al. Dual triggering with GnRH agonist plus hCG versus triggering with hCG alone for IVF/ICSI outcome in GnRH antagonist cycles: a systematic review and meta-analysis. Arch Gynecol Obstet. 2018; 298(1): 17-26.
  3. Ding N, Liu X, Jian Q, Liang Z, Wang F. Dual trigger of final oocyte maturation with a combination of GnRH agonist and hCG versus a hCG alone trigger in GnRH antagonist cycle for in vitro fertilization: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2017; 218: 92-98.
  4. Youssef MA, Van der Veen F, Al-Inany HG, Griesinger G, Mochtar MH, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011; 1: CD008046.
  5. Anaya Y, Mata DA, Letourneau J, Cakmak H, Cedars MI, Rosen MP. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols. J Assist Reprod Genet. 2018; 35(2): 297-307.
  6. Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding Andersen C. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropinreleasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril. 2010; 93(3): 847-854.
  7. Papanikolaou EG, Verpoest W, Fatemi H, Tarlatzis B, Devroey P, Tournaye H. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropinreleasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertil Steril 2011; 95(3): 1174-1177.
  8. Kasum M, Kurdija K, Orešković S, Čehić E, Pavičić-Baldani D, Škrgatić L. Combined ovulation triggering with GnRH agonist and hCG in IVF patients. Gynecol Endocrinol. 2016; 32(11): 861-865.
  9. Engmann L, Benadiva C. GnRH agonist (buserelin) or HCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2005; 20(11): 3258- 3260.
  10. Lamb JD, Shen S, McCulloch C, Jalalian L, Cedars MI, Rosen MP. Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, doubleblind, placebo-controlled trial. Fertil Steril. 2011; 95(5): 1655- 1660.
  11. Andersen CY. Effect of FSH and its different isoforms on maturation of oocytes from pre-ovulatory follicles. Reprod Biomed Online. 2002; 5(3): 232-239.
  12. Bianchi V, Dal Prato L, Maccolini A, Mazzone S, Borini A. Inadvertent recombinant human follicle stimulating hormone bolus instead of human chorionic gonadotrophin leads to the retrieval of competent oocytes in IVF program. Fertil Steril. 2009; 92(5): 1747-e1-3.
  13. Dashti S, Aflatoonian A, Tabibnejad N. Comparison of oocyte maturation trigger using follicle stimulating hormone plus human chorionic gonadotropin versus hCG alone in assisted reproduction rechnology cycles. Int J Fertil Steril. 2019; 13(2):102-107.
  14. Lin MH, Wu FS, Lee RK, Li SH, Lin SY, Hwu YM. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the livebirth rate for normal responders in GnRH-antagonist cycles. Fertil Steril. 2013; 100(5): 1296-1302.
  15. Practice Committee of the American Society for Reproductive Medicine, Practice Committee of the Society for Assisted Reproductive Technology. Criteria for number of embryos to transfer: a committee opinion. Fertil Steril. 2013; 99(1): 44-46.
  16. ESHRE Special Interest Group of Embryology and Alpha Scientists in Reproductive Medicine. The Vienna consensus: report of an expert meeting on the development of ART laboratory performance indicators. Reprod Biomed Online. 2017; 35(5): 494-510.
  17. ESHRE Clinic PI Working Group, Vlaisavljevic V, Apter S, Capalbo A, D'Angelo A, Gianaroli L, et al. The Maribor consensus: report of an expert meeting on the development of performance indicators for clinical practice in ART. Hum Reprod Open. 2021; 2021(3): hoab022.
  18. Juneau CR, Morin SJ, Franasiak JM, Landis JN, Molinaro TA, Scott RT. A ‘follicle-stimulating hormone boost’administered at the time of human chorionic gonadotropin trigger does not affect IVF cycle outcomes. Fertil Steril. 2016; 106(3): e189-190.
  19. Andersen CY, Humaidan P, Ejdrup HB, Bungum L, Grøndahl ML, Westergaard LG. Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction. Hum Reprod. 2006; 21(8): 2126-2130.